The prognostic significance of c-erbB-2 serum protein in metastatic breast cancer

Oncology

Volumn 55, Issue 1, 1997, Pages 33-38

  Fehm, Tanja ^a   Maimonis, Peter ^b   Katalinic, Alexander ^a   Jäger, Wolfram H ^a  

^a UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

^b Ciba Corning Diagnostics Corp   (United States)

Author keywords

c erbB 2; Metastatic breast cancer; Prognosis; Survival

Indexed keywords

ANTINEOPLASTIC AGENT; CYCLOPHOSPHAMIDE; FLUOROURACIL; METHOTREXATE; ONCOPROTEIN; PLASMA PROTEIN; STEROID RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; TUMOR MARKER;

ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER RECURRENCE; CANCER SURVIVAL; FEMALE; HUMAN; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MENOPAUSE; METASTASIS; MULTIVARIATE ANALYSIS; ONCOGENE C ERB; PRIORITY JOURNAL; PROGNOSIS; PROTEIN BLOOD LEVEL; TUMOR VOLUME; ADULT; ANALYSIS OF VARIANCE; BLOOD; BREAST TUMOR; CASE CONTROL STUDY; MIDDLE AGED; MORTALITY; PATHOLOGY; PREDICTION AND FORECASTING; RETROSPECTIVE STUDY; SURVIVAL;

ADULT; ANALYSIS OF VARIANCE; BREAST NEOPLASMS; CASE-CONTROL STUDIES; FEMALE; HUMANS; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; PROGNOSIS; RECEPTOR, ERBB-2; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 0030678593     PISSN: 00302414     EISSN: None     Source Type: Journal    
DOI: 10.1159/000011832     Document Type: Article

References (19)

1. Cousssens L, Yang-Feng TL, Lioa YC, Chen E, Gray A, McGrath J, Seeburg PH, Libermann TA, Schlessinger J, Francke U, Levison A, Ulrich A: Tyrosine kinase receptor with extensive homology to EGF receptor shares chromosomal location with neu oncogene. Science 1985; 230:1132-1139.
2. r tumor antigen. Nature 1984;312:513-516.
3. Borg A, Tandon AK, Sigurdsson H, Clark GM, Fernö M, Fuqua SAW, Killander D, McGuire WL: Her-2/neu amplification predicts poor survival in node-positive breast cancer. Cancer Res 1990;50:4332-4337.
4. Tandon AK, Clark GM, Chamness GC, Ullrich A, McGuire WL: Her-2/neu oncogene protein and prognosis in breast cancer. J Clin Oncol 1989;7:1120-1128.
5. Lovekin C, Ellis IO, Locker A, Robertson JFR, Bell J, Nicholson R, Gullick WJ, Elston CW, Blarney RW: c-erbB-2 oncoprotein expression in primary and advanced breast cancer. Br J Cancer 1991;63:439-443.
6. Toikkanen S, Helin H, Isola JJ, Joensuu H: Prognostic significance of her-2 oncoprotein expression in breast cancer: A 30 year follow-up. J Clin Oncol 1992;10:1044-1048.
7. Paik S, Hazan R, Fisher ER, Sass RE, Fisher B, Redmond C, Schlessinger J, Lippman ME, King CR: Pathologic findings from the national surgical adjuvant breast and bowel project: Prognostic significance of erbB-2 protein overexpression in primary breast cancer. J Clin Oncol 1990:1:103-112.
8. Kynast B, Binder L, Marx D, Zoll B, Schmoll HJ, Oellerich M, Schauer A: Determination of c-erbB-2 translational product p 185 in serum of breast cancer patients. J Cancer Res Clin Oncol 1993;119:249-252.
9. Carney WP, Hamer PJ, Petit D, Retos C, Greene R, Zabrecky JR, McKenzie S, Hayes D, Kufe D, DeLellis R, Naber S, Wolfe H: Detection and quantitation of the human neu protein. J Tumor Marker Oncol 1991;6:53-72.
10. Mori S, Mori Y, Mukaiyama T, Yamada Y, Sonobe Y, Matsushita H, Sakamoto G, Akiyama T, Ogowa M, Shiraishi M, Toyoshima K, Yamamoto T: In vitro and in vivo release of soluble erbB-2 protein from human carcinoma cells. Jpn J Cancer Res 1990;81:489-494.
11. Leitzel K, Teramoto Y, Sampson E, Mauceri J, Langton BC, Demers L, Podczaski E, Harvery H, Shambaugh S, Volas G, Weaver S, Lipton A: Elevated soluble c-erbB-2 antigen levels in the serum and effusions of a proportion of breast cancer patients. J Clin Oncol 1992;10:1436-1443.
12. Isola JJ, Holli K, Oksa H, Teramoto Y, Kallioniemi OP: Elevated erbB-2 oncoprotein levels in preoperative and follow-up serum samples define an aggressive disease course in patients with breast cancer. Cancer 1994;73:652-658.
13. Molina R, Jo J, Filella X, Zanon G, Pahisa J, Munoz M, Farrus B, Latre ML, Gimenez N, Hogue M, Estape J, Ballesta AM: c-erbB-2 oncoprotein in the sera and tissue of patients with breast cancer: Utility in prognosis. Anticancer Res 1996;16:295-300.
14. Narita T, Funahashi H, Satoh Y, Takagi H: c-erbB-2 protein in the sera of breast cancer patients. Breast Cancer Res Treat 1992;24:97-102.
15. Fehm T, Maimonis P, Weitz S, Teramoto V, Katalinic A, Jäger W: Influence of circulating c-erbB-2 serum protein on response to adjuvant chemotherapy in node-positive breast cancer patients. Breast Cancer Res Treat, in press.
16. Leitzel K, Teramoto Y, Konrad K, Chinchilli VM, Volas G, Grossberg H, Harvey H, Demers L, Lipton A: Elevated c-erbB-2 antigen levels and decreased response to hormone therapy of breast cancer. J Clin Oncol 1995;13:1129-1135.
17. Wright C, Cairns J, Cantwell BJ, Cattan AR, Hall AG, Harris AL, Horne CHW: Response to mitoxantrone in advanced breast cancer: Correlation with expression of c-erbB-2 protein and glutathione S-transferases. Br J Cancer 1992;65:271-274.
18. Wright C, Nicholson S, Angus B, Sainsbury JRC, Farndon J, Cairns J, Harris AL, Horne CHW: Relationship between c-erbB-2 protein product expression and response to endocrine therapy in advanced breast cancer. Br J Cancer 1992;65:118-121.
19. Gusterson BA, Gelber RD, Goldhirsch A, Price KN, Säve-Söderborgh J, Anbazhagan R, Styles J, Rudenstam CM, Golouh R, Reed R, Martinez-Tello F, Tiltman A, Torhorst J, Grigolato P, Bettelheim R, Neville AM, Bürki K, Castiglione M, Collins J, Lindtner J, Senn HJ: Prognostic importance of c-erbB-2 expression in breast cancer. J Clin Oncol 1992;7:1049-1056.